ALLR
Allarity Therapeutics, Inc.Company Information
- Company Name
- Allarity Therapeutics, Inc.
- CIK
- CIK0001860657
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ALLR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ALLR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,228,890
- Shares outstanding
- 15,910,724
- Ownership
- 7.72%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 3.65%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Cash | - | - | - | - | - | - | - | - | - | 0 | 0 | 1 | ||||||
| Cash Equivalents At Carrying Value | - | - | - | - | - | - | - | 18 | - | - | - | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 17 | 20 | 15 | 17 | 18 | 25 | 20 | - | 19 | - | 0 | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 32 | 35 | 18 | 20 | 21 | 29 | 22 | 20 | 21 | 2 | 2 | 4 | ||||||
| Restricted Cash Current | 10 | 10 | - | - | 0 | 3 | - | - | - | - | - | - | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Prepaid Expense Current | 3 | 4 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Income Taxes Receivable | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | - | - | - | - | - | - | 10 | 10 | 10 | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | - | - | - | - | 9 | ||||||
| Assets | 32 | 35 | 18 | 21 | 21 | 30 | 23 | 20 | 31 | 12 | 12 | 14 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | 0 | 0 | - | - | 10 | - | ||||||
| Accounts Payable Current | 4 | 4 | 4 | 5 | 5 | 4 | 4 | 5 | 8 | 11 | 8 | 6 | ||||||
| Accrued Liabilities Current | 2 | 2 | 3 | 3 | 3 | 5 | 5 | 1 | 1 | 2 | 1 | 1 | ||||||
| Taxes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 29 | 28 | 8 | 9 | 9 | 11 | 11 | 7 | 11 | 18 | 14 | 16 | ||||||
| Short Term Borrowings | 21 | 20 | - | - | - | - | - | - | - | - | - | - | ||||||
| Derivative Liabilities Current | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | ||||||
| Convertible Notes Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | - | ||||||
Non Current Liabilities | ||||||||||||||||||
| Liabilities | 29 | 28 | 8 | 9 | 9 | 11 | 11 | 7 | 11 | 18 | 15 | 17 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Deficit Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Additional Paid In Capital | 145 | 144 | 144 | 144 | 141 | 141 | 131 | 125 | 120 | 91 | 90 | 88 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -2 | -2 | -1 | -0 | -1 | -1 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -136 | -133 | -130 | -127 | -124 | -122 | -119 | -112 | -100 | -98 | -94 | -93 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 4 | 7 | 10 | 12 | 12 | 19 | 12 | 13 | 20 | -6 | -3 | -3 | ||||||
Redeemable Preferred Stock500000 Shares Authorized | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | 0 | 0 | - | 2 | 2 | 2 | ||||||
| Treasury Stock Common Value | -3 | -3 | -3 | -3 | -3 | - | 0 | - | - | - | - | - | ||||||
| Liabilities And Stockholders Equity | 32 | 35 | 18 | 21 | 21 | 30 | 23 | 20 | 31 | 12 | 12 | 14 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | - | 0 | 0 | 1 | -0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 750 | 750 | 750 | 750 | 750 | ||||||
| Common Stock Shares Issued | 19 | 19 | 19 | 19 | 17 | 17 | 7 | 3 | 35 | 0 | 10 | 4 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | 0.00 | - | - | 0.00 | 0.00 | ||||||
| Shares Outstanding | 16 | 16 | 16 | 16 | 15 | 17 | 7 | 3 | 35 | 0 | 10 | 4 | ||||||
| Series C Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | 0 | 0 | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | 0 | 0 | - | - | 0 | 0 | ||||||
| Preferred Stock Liquidation Preference Value | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Treasury Stock Common Shares | 3 | 3 | 3 | 3 | 2 | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAllarity Therapeutics, Inc. (ALLR) — SEC Financial Statements & Analysis
Allarity Therapeutics, Inc. (ALLR) is a pharmaceutical preparations company, incorporated in DE. Allarity Therapeutics, Inc. trades on Nasdaq as: ALLR. Allarity Therapeutics, Inc. (ALLR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Allarity Therapeutics, Inc. carries a market cap of $20.52M, a P/E ratio of -1.66x, a P/B ratio of 5.80x, a P/S ratio of 820.99x, an enterprise value of $25.83M, and an EV/EBITDA multiple of -2.39x. On profitability, it posts an operating margin of -43180.00%, a net margin of -49336.00%, a Return on Equity (ROE) of -157.08%, a Return on Assets (ROA) of -46.26%, and a Return on Invested Capital (ROIC) of -471.14%. Per share, it reports EPS of $-0.78, diluted EPS of $-0.85, free cash flow per share of $-0.87, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -50.06% year-over-year and EPS growth of -51.21% year-over-year. On the balance sheet, it maintains a current ratio of 1.11x, a quick ratio of 0.99x, working capital of $3.15M, a debt-to-equity ratio of 8.08x, a debt ratio of 0.89, an interest coverage ratio of -10.15x, free cash flow of $-13.77M (TTM), and net debt of $5.30M. Figures sourced from SEC EDGAR.
- Market Cap
- $20.52M
- P/E TTM
- -1.66x
- EPS TTM
- $-0.78
- P/B TTM
- 5.80x
- ROE TTM
- -157.08%
- ROA TTM
- -46.26%
- Debt To Equity
- 8.08x
- Free Cash Flow TTM
- $-13.77M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Allarity Therapeutics, Inc. in?
Allarity Therapeutics, Inc. (ALLR) operates in the Pharmaceutical Preparations industry.
What exchange does ALLR trade on?
Allarity Therapeutics, Inc. (ALLR) trades on the Nasdaq.
Where is Allarity Therapeutics, Inc. incorporated?
Allarity Therapeutics, Inc. is incorporated in DE.
When was Allarity Therapeutics, Inc. (ALLR)'s most recent SEC filing?
Allarity Therapeutics, Inc. (ALLR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is ALLR's market cap?
Allarity Therapeutics, Inc. (ALLR) has a market capitalization of $20.52M as of 2026-06-30.
What is ALLR's EPS (earnings per share)?
Allarity Therapeutics, Inc. (ALLR)'s trailing twelve month EPS is $-0.78 as of 2026-06-30.
What is ALLR's ROE (return on equity)?
Allarity Therapeutics, Inc. (ALLR)'s trailing twelve month Return on Equity (ROE) is -157.08% as of 2026-06-30.
What is ALLR's ROA (return on assets)?
Allarity Therapeutics, Inc. (ALLR)'s trailing twelve month Return on Assets (ROA) is -46.26% as of 2026-06-30.
What is ALLR's ROIC (return on invested capital)?
Allarity Therapeutics, Inc. (ALLR)'s trailing twelve month Return on Invested Capital (ROIC) is -471.14% as of 2026-06-30.
What is ALLR's EV/EBITDA?
Allarity Therapeutics, Inc. (ALLR)'s trailing twelve month EV/EBITDA is -2.39x as of 2026-06-30.